Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN

Key Points

• Park National Corp OH reduced its stake in AstraZeneca by 12.6% in Q4, selling 20,162 shares and ending the period with 139,437 shares valued at $12.82 million.
• AstraZeneca announced a $1.595 dividend to be paid on March 23 to shareholders of record on February 20 (ex-dividend February 20).
• Analyst consensus shows nine Buys and one Sell, giving AstraZeneca an average rating of Moderate Buy and an average target price of $95.75 (MarketBeat data).

Park National Corp OH reduced its position in shares of Astrazeneca Plc (NYSE:AZN - Free Report) by 12.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 139,437 shares of the company's stock after selling 20,162 shares during the period. Park National Corp OH's holdings in Astrazeneca were worth $12,818,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Park Avenue Securities LLC grew its holdings in Astrazeneca by 2.8% during the 4th quarter. Park Avenue Securities LLC now owns 106,786 shares of the company's stock worth $9,817,000 after acquiring an additional 2,910 shares during the period. Miller Global Investments LLC bought a new position in shares of Astrazeneca in the 4th quarter worth $709,000. GAMMA Investing LLC grew its stake in shares of Astrazeneca by 18.2% during the fourth quarter. GAMMA Investing LLC now owns 13,282 shares of the company's stock worth $1,221,000 after purchasing an additional 2,047 shares during the period. Triumph Capital Management acquired a new stake in shares of Astrazeneca during the third quarter worth $25,000. Finally, Hudson Bay Capital Management LP increased its holdings in Astrazeneca by 40.5% in the third quarter. Hudson Bay Capital Management LP now owns 444,874 shares of the company's stock valued at $34,131,000 after purchasing an additional 128,256 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Astrazeneca in a report on Friday, February 6th. TD Cowen reiterated a "buy" rating on shares of Astrazeneca in a research report on Wednesday. HSBC reissued a "buy" rating and set a $108.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 10th. Morgan Stanley reaffirmed an "overweight" rating and issued a $103.00 target price on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, Citigroup assumed coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They set a "buy" rating on the stock. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $95.75.

Astrazeneca Stock Up 0.2%

AZN stock opened at $188.76 on Friday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The stock has a market cap of $292.75 billion, a PE ratio of 28.82, a PEG ratio of 1.42 and a beta of 0.32. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca's dividend payout ratio (DPR) is 66.26%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.